By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Afferent Pharmaceuticals 

29 Newbury Street
Suite 301
Boston  Massachusetts  02116  U.S.A.
Phone: 617-859-3099 Fax: 617-859-2891




Company News
Afferent Pharmaceuticals Expands Executive Leadership Team With Appointments Of Prabha N. Ibrahim, PhD, As Chief Technology Officer And Michelle Carpenter, JD, RAC, As Vice President, Regulatory Affairs And Project Management 11/19/2015 10:09:47 AM
Afferent Pharmaceuticals Announces Phase 2 Clinical Trial With AF-219 In Cough In Idiopathic Pulmonary Fibrosis (IPF) Patients 11/11/2015 11:34:00 AM
Afferent Pharmaceuticals Announces Positive Results In Phase 2b Chronic Cough Trial 9/28/2015 1:30:17 PM
Afferent Pharmaceuticals Raises $55 Million In Oversubscribed Crossover Financing 7/8/2015 8:22:45 AM
Afferent Pharmaceuticals Announces The Election Of Dr. Peter Hirth To The Company’s Board Of Directors 12/3/2014 8:45:11 AM
Afferent Pharmaceuticals Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency By 75% in Chronic Cough Is Published In The Lancet 11/25/2014 6:37:44 AM
Afferent Pharmaceuticals Names Kathleen Sereda Glaub As Chief Executive Officer 9/10/2014 6:27:42 AM
Afferent Pharmaceuticals Names Michael M. Kitt, M.D., as Chief Medical Officer 11/6/2013 9:15:37 AM
Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company’s Lead P2X3 Antagonist, AF-219 9/9/2013 9:44:08 AM
Afferent Pharmaceuticals Presents Data Supporting Use of P2X3 Antagonists in Reducing Bone Cancer Pain 9/1/2010 8:42:05 AM